1190 related articles for article (PubMed ID: 27445460)
1. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
[TBL] [Abstract][Full Text] [Related]
2. Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial.
Chen Y; Ye J; Zhu Z; Zhao W; Zhou J; Wu C; Tang H; Fan M; Li L; Lin Q; Xia Y; Li Y; Li J; Jia H; Lu S; Zhang Z; Zhao K
J Clin Oncol; 2019 Jul; 37(20):1695-1703. PubMed ID: 30920880
[TBL] [Abstract][Full Text] [Related]
3. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients.
Honing J; Smit JK; Muijs CT; Burgerhof JGM; de Groot JW; Paardekooper G; Muller K; Woutersen D; Legdeur MJC; Fiets WE; Slot A; Beukema JC; Plukker JTM; Hospers GAP
Ann Oncol; 2014 Mar; 25(3):638-643. PubMed ID: 24492674
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma-the ESO-shanghai 1 trial protocol.
Chen Y; Zhu Z; Zhao W; Li L; Ye J; Wu C; Tang H; Lin Q; Li J; Xia Y; Li Y; Zhou J; Zhao K
Radiat Oncol; 2018 Feb; 13(1):33. PubMed ID: 29482649
[TBL] [Abstract][Full Text] [Related]
5. Comparison of efficacy and toxicity profiles between paclitaxel/lobapoatin- and cisplatin/5-fluorouracil-based concurrent chemoradiotherapy of advanced inoperable oesophageal cancer.
Yang JS; Wang T; Qiu MQ; Li QL
Intern Med J; 2015 Jul; 45(7):757-61. PubMed ID: 25851492
[TBL] [Abstract][Full Text] [Related]
6. A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma.
Wang HY; Yao ZH; Tang H; Zhao Y; Jin SL; Zhou WP; Yao SN; Yang SJ; Liu YY; Luo SX
Oncotarget; 2017 Jan; 8(5):7540-7547. PubMed ID: 27902478
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
[TBL] [Abstract][Full Text] [Related]
8. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer: A Randomized Clinical Trial.
Ai D; Ye J; Wei S; Li Y; Luo H; Cao J; Zhu Z; Zhao W; Lin Q; Yang H; Zheng X; Zhou J; Huang G; Li L; Li J; Zhang Z; Zhou G; Gu D; Du M; Mo M; Jia H; Zhang Z; Zhao K
JAMA Netw Open; 2022 Feb; 5(2):e220120. PubMed ID: 35188552
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinoma.
Fang M; Song T; Liang X; Lv S; Li J; Xu H; Luo L; Jia Y
Oncotarget; 2017 Jun; 8(23):37080-37090. PubMed ID: 28415745
[TBL] [Abstract][Full Text] [Related]
11. Concurrent cisplatin and 5-fluorouracil versus concurrent cisplatin and docetaxel with radiotherapy for esophageal squamous cell carcinoma: a propensity score-matched analysis.
Zhang P; Xi M; Li QQ; Hu YH; Guo X; Zhao L; Liu H; Liu SL; Luo LL; Liu Q; Liu MZ
Oncotarget; 2016 Jul; 7(28):44686-44694. PubMed ID: 27183916
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study.
Lyu J; Li T; Wang Q; Li F; Diao P; Liu L; Li C; Lang J
Radiat Oncol; 2018 Nov; 13(1):233. PubMed ID: 30477531
[TBL] [Abstract][Full Text] [Related]
13. Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma.
Kumabe A; Fukada J; Kota R; Koike N; Shiraishi Y; Seki S; Yoshida K; Kitagawa Y; Shigematsu N
Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29228166
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
[TBL] [Abstract][Full Text] [Related]
15. Intensity-modulated radiotherapy combined with paclitaxel and platinum treatment regimens in locally advanced esophageal squamous cell carcinoma.
Chen J; Su T; Lin Y; Wang B; Li J; Pan J; Chen C
Clin Transl Oncol; 2018 Mar; 20(3):411-419. PubMed ID: 28779422
[TBL] [Abstract][Full Text] [Related]
16. Comparison of definite chemoradiation therapy with carboplatin/paclitaxel or cisplatin/5-fluoruracil in patients with squamous cell carcinoma of the esophagus.
Münch S; Pigorsch SU; Devečka M; Dapper H; Weichert W; Friess H; Braren R; Combs SE; Habermehl D
Radiat Oncol; 2018 Aug; 13(1):139. PubMed ID: 30068371
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of concurrent chemoradiotherapy combined with a weekly paclitaxel and 5-fluorouracil regimen to treat patients with advanced oesophageal carcinoma.
Xia Y; Li YH; Chen Y; Zhang JH; Liu Q; Deng JY; Ai TS; Zhu HT; Fan JH; Badakhshi H; Zhao KL
Radiat Oncol; 2017 Mar; 12(1):47. PubMed ID: 28270162
[TBL] [Abstract][Full Text] [Related]
18. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of paclitaxel plus cisplatin with concurrent radiotherapy for loco-regional esophageal squamous cell carcinoma.
Zhu HT; Ai DS; Tang HR; Badakhshi H; Fan JH; Deng JY; Zhang JH; Chen Y; Zhang Z; Xia Y; Guo XM; Jiang GL; Zhao KL
World J Gastroenterol; 2017 Jan; 23(3):540-546. PubMed ID: 28210091
[TBL] [Abstract][Full Text] [Related]
20. Tolerability and efficacy of concurrent chemoradiotherapy comparing carboplatin/paclitaxel versus platinum/5-FU regimen for locally advanced esophageal and esophagogastric junction cancers.
Tamtai A; Jiarpinitnun C; Hiranyatheb P; Unwanatham N; Sirachainun E; Supsamutchai C; Pattaranutaporn P; Ngamphaiboon N
Med Oncol; 2017 Sep; 34(9):157. PubMed ID: 28785986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]